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Toll-like receptors (TLRs) play prominent roles in
initiating immune responses to infection, but their
roles in particular cell types in vivo are not estab-
lished. Here we report the generation of mice selec-
tively lacking the crucial TLR-signaling adaptor
MyD88 in dendritic cells (DCs). In these mice, the
early production of inflammatory cytokines, espe-
cially IL-12,was substantially reduced after TLRstim-
ulation. Whereas the innate interferon-g response of
natural killer cells and of natural killer T cells and the
Th1 polarization of antigen-specific CD4+ T cells
were severely compromised after treatment with
a soluble TLR9 ligand, they were largely intact after
administration of an aggregated TLR9 ligand. These
results demonstrate that the physical form of a TLR
ligand affects which cells can respond to it and that
DCs and other innate immune cells can respond via
TLRs and collaborate in promoting Th1 adaptive
immune responses to an aggregated stimulus.
INTRODUCTION
The immune systems of multicellular organisms must recognize
the presence of infectious agents and direct effector mecha-
nisms against those agents. In recent years, Toll-like receptors
(TLRs), which recognize a variety of pathogen-associated mo-
lecular patterns of infectious agents, have emerged as critical
for this recognition (Akira et al., 2006). In mammalian tissues,
TLRs are highly expressed by resident immune cells, including
dendritic cells (DCs), tissue macrophages, and mast cells, and
to a lesser degree by other cell types including fibroblasts, epi-
thelial cells, and endothelial cells (Takeda et al., 2003). Upon
binding ligands, all known TLRs except for TLR3 can activate
downstream signaling cascades through the adaptor protein
MyD88 to induce production of inflammatory cytokines by mac-
rophages, DCs, and, to a lesser extent, other cell types. These
cytokines, including interferon-a (IFN-a), interferon-b (IFN-b), in-
terleukin 12 (IL-12), tumor necrosis factor a (TNF-a), interleukin 6
(IL-6), and interleukin 1 (IL-1) attract innate immune cells and/or
promote the initiation and polarization of adaptive immune
responses (Akira, 2006). Indeed, MyD88-deficient mice have
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ample, immunization of mice with TLR ligands, such as CpG or
LPS, or with complete Freund’s adjuvant, which contains ligands
for TLR2 and TLR4, induces naive CD4 T cells to differentiate into
T cell helper 1 (Th1) effector cells, and this is severely compro-
mised in mice deficient in MyD88 (Iwasaki andMedzhitov, 2004).
DCs are known to be the main antigen-presenting cells that
activate naive T cells in all or most circumstances (Jung et al.,
2002; Itano and Jenkins, 2003), but how TLRs promote their mat-
uration and ability to polarize CD4+ T cells to Th1 effector cells is
less well understood. During infection, microbial TLR ligands can
induce DCs to mature, a response characterized by upregulation
of surface major histocompatibility complex (MHC)-peptide
complexes and costimulatory molecules involved in activating
T cells and of the chemokine receptor CCR7, aswell as bymigra-
tion to the T cell zones in the draining lymph node (Iwasaki and
Medzhitov, 2004). Once in lymphoid tissue, mature DCs promote
activation of antigen-specific T cells and secrete cytokines and
other factors that can promote effector T cell differentiation.
However, microbial TLR ligands can also activate other tissue-
resident cell types to secrete inflammatory mediators, such as
IFN-a, IFN-b, and TNF-a, which can also promote DCs to mature
and enable them to promote T cell immune responses, providing
an indirect mode of activation of DCs (Kapsenberg, 2003). In
order to distinguish the role of direct and indirect modes of
TLR activation of DCs, Spo¨rri and Reis e Sousa employed
mixed-bone-marrow chimeric mice, which were treated with
a synthetic TLR9 ligand. They found that the indirect mode of
stimulation was sufficient for maturation of DCs in their experi-
mental system but was insufficient to promote a robust Th1 or
Th2 effector cell response (Spo¨rri and Reis e Sousa, 2005).
This study suggested that direct TLR stimulation of antigen-pre-
senting DCs, also called ‘‘TLR licensing’’ (Heath and Villadangos,
2005), is important for promoting a robust T cells response even
in the context of inflammatory cytokines produced by neighbor-
ing cells. To address inmore detail the role of TLR signaling in dif-
ferent cell types for immune responses, we created a conditional
allele of the mouse Myd88 gene. By crossing this allele with
a DC-specific Cre transgene, CD11cCre (Itgax-Cre) (Caton
et al., 2007), we have generated highly DC-specific MyD88-defi-
cientmice. Using thesemice, we have found thatMyD88-depen-
dent signaling in DCs plays a very important role in innate cyto-
kine production and Th1 polarization of antigen-specific CD4+ T
cells, but that in some circumstances non-DC cell types can
cooperate with DCs to support these immune responses.
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Generation of theMyd88 Flox Allele and Selective
Deletion of MyD88 in DCs
To create a conditional allele of mouseMyd88, we introduced 34
base pair LoxP sites on either side of exon 3 of the gene by ho-
mologous recombination in embryonic stem cells, which were
then used to generate chimeric mice by standard procedures
(Figures S1A and S1B available online). Splenic DCs from mice
with two copies of this targeted allele expressed MyD88 protein
at amounts indistinguishable from wild-type DCs (Figure S1C),
indicating that this allele is likely to function normally in the
absence of Cre-mediated deletion.
To test the ability of the Cre recombinase to delete exon 3 of
the Myd88 flox (Myd88fl) allele, we generated mice carrying
both the Myd88fl allele and the Vav-Cre transgene, which is ex-
pressed in all cells of the hematopoietic lineage (de Boer et al.,
2003). Splenocytes fromMyd88fl/flVav-Cre mice exhibited nearly
complete deletion as judged by loss of MyD88 protein expres-
sion (Figure S1C).
To study the role of MyD88 in DCs, we crossed mice with the
Myd88fl allele to mice carrying the CD11c-Cre transgene, which
is preferentially expressed in DCs (Caton et al., 2007). The num-
bers of DCs and of their subsets were unchanged in the spleen
and lymph nodes of the Myd88fl/flCD11c-Cre mice (Table S2
and data not shown). The deletion of theMyd88fl allele wasmea-
sured by a quantitative PCR assay, which detected the amount
of residual Myd88 exon 3 sequence in genomic DNA. We found
that over 94% of the Myd88fl allele was deleted in the conven-
tional DCs (cDCs) and around 80%was deleted in plasmacytoid
DCs (pDCs), whereas deletion was not detected in splenic mac-
rophages and neutrophils or in naive or activated CD4+ T cell
(Table 1 and Table S1). These results were corroborated by
Table 1. Deletion Efficiency in DC-Myd88/ Mice
Cell Population DDCt Residual Myd88fl % Deletion
myd88fl/fl splenocytes 0 1 0
cDC #1 5.185 0.027 97.3
cDC #2 4.885 0.034 96.6
pDC #1 2.465 0.181 81.9
pDC #2 2.565 0.169 83.1
Mf+PMN #1 0.070 0.953 4.7
Mf+PMN #2 0.131 1.095 0*
Mf+PMN #3 0.030 0.979 2.1
NK #1 0.110 0.927 7.3
NK #2 0.115 1.083 0*
NK #3 0.035 1.025 0*
Quantitative PCRmeasurement of the amount of the residual ‘‘floxed’’ re-
gion in different cell types of several different DC-Myd88/mice. All cells
were FACS purified from spleen. cDC: CD11chiB220CD19. pDCs:
CD11cintB220+Ly6C+CD19. Macrophages and neutrophils (Mf+PMN):
CD11cCD11b+. NK cells: NK1.1+TCRb. DDCt is the difference of
the normalized threshold-cycle number (Ct) between the cell sample
of the Myd88fl/flCD11c-Cre mice and that of the Myd88fl/fl control mice.
The values of the residualMyd88fl allele were calculated as 2DDCt.% de-
letion values were calculated as (1 residualMyd88fl)3 100. *, when the
calculated number of % deletion was negative, a value of ‘‘0’’ was as-
signed.measurement of MyD88 protein in purified cells (Figure S1D).
Natural killer (NK) cells also express CD11c, although at lower
amounts than DCs (Laouar et al., 2005). We could not detect
deletion in purified NK cells (Table 1). These results demonstrate
that there is highly selective deletion in DCs of theMyd88fl/flCD11c-
Cre mice, and, therefore, these mice are referred to here as
DC-Myd88/ mice.
Inflammatory-Cytokine Response to TLR Stimulation
in the DC-Myd88/ Mice
TLR stimulation induces DCs to produce cytokines, including
IL-12, which promotes IFN-g production and polarization of ac-
tivated CD4+ T cells to the Th1 effector type. To test the impor-
tance of MyD88-dependent signaling in DCs for this response,
we injected DC-Myd88/ mice and control mice intravenously
(i.v.) with CpG-containing oligodeoxynucleotide ODN1826
(CpG), a TLR9 ligand that signals solely through a MyD88-de-
pendent pathway. One hour later, we examined splenic DCs
for IL-12 and/or IL-23 production by staining intracellular IL-
12p40. The splenic CD8a+ DCs in wild-type mice had a robust
induction of IL-12p40, but this response was completely defec-
tive in the DC-Myd88/ mice (Figure 1A). This result confirmed
that ablation of MyD88 function in CD8a+ DCs had been
achieved and that this rapid response requires MyD88 signaling
within DCs. Next, we examined the contribution of DCs to
systemic IL-12 production in vivo. Two hours after intrave-
nous injection of CpG, the amounts of IL-12p70 in the serum of
DC-Myd88/ mice were below detection limit, whereas the
amounts in the control mice increased significantly (p < 0.01)
(Figure 1B), indicating that the DCs are themajor cell type to rap-
idly produce functional IL-12 in vivo after TLR9 stimulation via the
blood stream. Next, we examined the IL-12p40 response of
these mice at 1 hr after stimulation with ligands for TLR1+TLR2,
TLR4, TLR5, TLR7, or TLR9.We found that the levels of IL-12p40
mRNA induced in total splenocytes in response to stimulation by
these TLR ligands administered systemically were all greatly
reduced (5–303) in the DC-Myd88/ mice compared to the
control mice (Figure 1C). These results indicate that DCs are
the major cell type in the spleen to rapidly produce IL-12p40 in
response to the stimulation of most TLRs.
Although DCs are generally thought to be major producers of
IL-12, other splenic cell types such as macrophages are also
capable of producing substantial amounts of inflammatory cyto-
kines, including IL-1b, IL-6, and TNF-a in response to TLR stim-
ulation. Therefore, we examined the induction of several proin-
flammatory cytokines after systemic administration of CpG.
Surprisingly, we found that DC-Myd88/ mice exhibited sub-
stantially reduced mRNA induction of most tested cytokines in
the spleen (Figure 1D), as well as greatly decreased amounts
of cytokines in the serum (Figure S2 and data not shown). Similar
results were also found with ligands for TLR1+TLR2, TLR4,
TLR5, and TLR7 (data not shown). These results indicate that
DCs play a surprisingly major role in early innate immune cyto-
kine responses upon systemic administration of TLR ligands.
An Aggregated Form of the TLR9 Ligand CpG Induces
Distinct Inflammatory Responses
In the experiments described above, we used a synthetic TLR9
ligand that acts in monomeric form (Klinman, 2004). However,
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(A and B) IL-12 expression in control or DC-Myd88/ mice after i.v. injection with PBS or CpG. (A) Splenocytes isolated 1 hr after injection were stained for
intracellular IL-12p40. Shown are representative FACS plots of gated CD11chi DCs for one of six mice per group analyzed on two separated days. (B) Amounts
of IL-12p70 in the serum ofmice, asmeasured by ELISA, at 2 hr after i.v. injection of CpG (n = 5 for DC-Myd88/mice). Amounts of IL-12p70 in PBS-treatedmice
all were under detection limit (not shown).
(C) Induction of IL-12p40 mRNA in the spleen at 1 hr after i.v. injection of Pam3CSK4 (TLR1+TLR2), LPS (TLR4), flagellin (TLR5), CpG (TLR9), or intraperitoneal
(i.p.) injection of Imiquimod (TLR7).
(D) Induction of inflammatory-cytokine mRNA in the spleen at 1 hr after i.v. injection of CpG. n-fold induction (mean + standard deviation [SD] of three mice) is
relative to the abundance in vehicle-treated mice. Numbers on top of the bars are the n-fold difference between the induction levels in the control and the
DC-Myd88/ mice. Statistical comparison is between the DC-Myd88/ mice and the control mice. *, p < 0.05; **, p < 0.01. Data are representative of two
separate experiments.many natural TLR ligands exist in complexed forms, which could
interact differently with host immune cells. Tomake a complexed
form of a TLR ligand, we encapsulated the TLR9 ligand CpGwith
a cationic lipid, 1,2-dioleoyloxy-3-trimethylammonium-propane-
methylsulfate (DOTAP) (hereby referred to as CpG-DOTAP).
It hasbeen shown that responses toCpG-DOTAP, like responses
to uncomplexed CpG, are dependent on TLR9 and MyD88
(Yasuda et al., 2005)(Honda et al., 2005), a point that we
confirmedwithMyd88/mice (data not shown). Using a fluores-
cently labeled CpG, we found that DOTAP enhanced uptake
of CpG in splenic cell types such as CD11b+ DCs, pDCs,
macrophages, and monocytes (Figure 2A). Complexing CpG
with DOTAP also changed the profile of the responding cell
types. For example, injecting CpG-DOTAP intravenously in-
duced both splenic CD8a+ DCs and CD11b+ DCs to express
IL-12p40 intracellularly in wild-type mice (Figure 2B), a feature
that is similar to LPS, a lipid ligand for TLR4 that also forms aggre-
gated membrane-like structures (Skelly et al., 1979), but unlike
soluble CpG (Figure 2B). As expected, the induction of intracellu-
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because it was abolished in bothCD8a+ DCs andCD11b+DCs of
the DC-Myd88/mice (Figure S3A). Interestingly, we also found
that CpG-DOTAP induced intracellular TNF-a in CD11b+ DCs
and in an additional population of cells that were CD11b+F4/
80+Ly6C+SSC (side light scatter)loCD11cNK1.1B220, con-
sistent with a monocyte phenotype (Figure 2C), suggesting that
DOTAP also enhances the responses to CpG of other cell types
in addition to CD11b+ DCs. This TNF-a response was not im-
paired in the monocytes, but was ablated in DCs in the DC-
Myd88/ mice (Figure 2C and Figure S3B), confirming the DC
specificity of MyD88 ablation by CD11c-Cre.
Next, to examine a broader range of inflammatory-cytokine
responses to this complexed form of TLR9 ligand, we measured
inflammatory-cytokine mRNA induction in the spleen after inject-
ing the mice i.v. with CpG-DOTAP. Interestingly, the inductions
of many cytokines, including IL-23p19, IL-6, and TNF-a, were
attenuated to a much lesser degree in the DC-Myd88/ mice
stimulated in this way (Figure 2D) than in mice stimulated with
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TLR9 on non-DC cell types in the spleen more effectively than
uncomplexed CpG. In agreement with a previous report (Honda
et al., 2005), theCpG-DOTAPcomplex strongly induced IFN-b and
IFN-a4 mRNA (Figure 2D), whereas soluble CpG did so poorly
(Figure 1D). By measuring the mRNA induction in different cell
types, we found that pDCs were the major type I IFN-producing
cell type in the spleen in response to CpG-DOTAP, but other cell
types including DCs andmacrophages could also produce these
cytokines (Table S2). This type I IFN response was abolished in
DCs and was substantially reduced in the pDCs in the DC-
Myd88/mice (Table S2), but the overall induction in the spleen
was still substantially higher than in the wild-type mice stimu-
lated with CpG alone (Figure 2D).
Role of MyD88 in DCs for the IFN-g Response
to TLR Ligands by NK Cells and NKT Cells
In the early inflammatory-cytokine response to systemic admin-
istration of TLR agonists, we consistently observed strongly
attenuated IL-12p40 expression in the DC-Myd88/ mice.
Because IL-12 is a potent inducer of IFN-g production, we next
asked how IFN-g production in response to TLR stimulation
was affected by ablation of MyD88 selectively in DCs. To identify
the cellular source of IFN-g after TLR stimulation, we stained
splenocytes for intracellular IFN-g at different time points after
injecting mice with CpG. Consistent with a previous report
(Laouar et al., 2005), we found that NK cells were the major
IFN-g-producing cells in the spleen (Figure S4), starting only
a few hours after TLR ligand administration. NKT cells also ex-
pressed IFN-g, but to a substantially lesser degree both in terms
of the number of IFN-g-positive cells in the spleen and of the
amount of IFN-g detected per cell (Figure S4). In contrast, CD4+
T cells, CD8+ T cells, and DCs did not express a large amount
of IFN-g in response to CpG at these early time points. To exam-
ine the role of MyD88 signaling in DCs for this in vivo innate IFN-g
response, we measured IFN-g production by NK cells and NKT
cells after TLR stimulation in the DC-Myd88/ mice. Interest-
ingly, we found that the IFN-g response was totally dependent
on MyD88 function in DCs when the mice were stimulated with
CpG (Figure 3A and data not shown for NKT cells). Similar results
were seen with Pam3CSK4 (TLR1+TLR2 agonist) and Imiquimod
(TLR7 agonist) (data not shown). As expected, this IFN-g re-
sponse was abolished in mice deficient in IL-12p35 (Figure 3B).
These results suggest that the response of NK cells or NKT cells
to direct TLR stimulationwas not sufficient to produce IFN-g, and
instead these cells needed to be stimulated by cytokines such as
IL-12 produced by DCs. When the response to i.v. injection of
CpG-DOTAP was examined, the number of IFN-g-positive cells
was substantially enhanced compared to the response to CpG
alone (Figure 3A and data not shown for NKT cells). This en-
hanced IFN-g response was fully MyD88 dependent and was to
a large part dependent on type I IFN signaling (Figure 3B). Inter-
estingly, ablating MyD88 in DCs only partially reduced the
IFN-g response to CpG-DOTAP administered i.v. (Figure 3A), in-
dicating that MyD88 signaling in cell types other than DCs plays
a substantial role in this response. Stimulation with LPS also in-
duced a strong IFN-g response from NK cells in the control
mice (Figure 3A, data not shown for NKT cells). This IFN-g re-
sponse was also only partially reduced in the DC-Myd88/mice (Figure 3A), but was almost completely abolished in the
Myd88/ mice and in theMyd88fl/flVav-Cremice (Figure S5).
DC Maturation in Response to TLR Stimulation
in the DC-Myd88/ Mice
We next assessed the importance of MyD88 signaling in DCs for
their ability to prime naive CD4+ T cells. DC maturation in the
spleen was examined after the mice were intravenously injected
with CpG or CpG-DOTAP. In control mice, both CpG and CpG-
DOTAP induced increased expression of CD86, CD40, and, to
a lesser extent, class II MHC molecules in splenic cDCs, but
the response to CpG-DOTAP was much stronger (Figure 4A).
These responses were attenuated in the DC-Myd88/ mice,
but in the mice stimulated with CpG-DOTAP, a subset of DCs
in the spleen, including both CD8a+ and CD11b+ DCs (data not
shown), induced expression of CD86 to a similar degree to that
of the DCs from the stimulated MyD88-expressing mice
(Figure 4B). These results indicate that cytokines from other cell
types surrounding DCs can partially compensate for the loss of
direct TLR stimulation to induce someDCs tomature in response
to this potent TLR stimulus. It should be noted that the response
to CpG-DOTAP remained fully MyD88 dependent because there
was no DC maturation in Myd88/ mice (Figure 4B).
Development of CD4+ T Cell Effector Function
in the DC-Myd88/ Mice
To examine the effect of defective TLR signaling in DCs on the
activation of adaptive immune responses, we adoptively trans-
ferred CFSE-labeled ovalbumin (OVA)-specific T cell receptor
(TCR)-transgenic OT-II T cells into DC-Myd88/ and control
mice and then immunized the mice with OVA by using either
CpG or CpG-DOTAP as adjuvants. The proliferation and effector
polarization of OT-II T cells in the spleen were analyzed 4 and 7
days later. We found that both immunization protocols led to ac-
cumulation of increased numbers of OT-II T cells in the spleen of
wild-type recipient mice compared with mice immunized with
OVA alone (data not shown). Most of the transferred OT-II T cells
had divided multiple times by day 4 after immunization with OVA
plus either CpG or CpG-DOTAP, as indicated by CFSE dilution
(Figure 5A). However, we consistently found that more OT-II T
cells had accumulated in the spleen of the control mice immu-
nized with CpG-DOTAP than in the control mice immunized
with CpG (Figure 5B), correlating with the fact that more DCs
hadmatured in the CpG-DOTAP-treatedmice (Figure 4). This ex-
pansion and survival of antigen-specific naive CD4+ T cells was
clearly decreased in the DC-Myd88/ mice immunized with
OVA and CpG compared to the control mice (Figure 5B). Similar
results were seen on day 7 (data not shown). In contrast, the re-
sponse was not compromised by MyD88 deficiency in DCs in
mice immunized with OVA and CpG-DOTAP (Figure 5B).
In addition, OT-II T cell effector function was evaluated 4 and 7
days after immunization by intracellular staining of IFN-g after
in vitro restimulation for 4 hr. We found that selective deletion of
MyD88 in DCs impaired the Th1 effector differentiation of OT-II T
cells when CpG was used as adjuvant, as indicated by a reduced
number of IFN-g-producing cells on day 4 (Figure 5), and similarly
onday7 (datanotshown). Incontrast,nosuchdifferencewasfound
whenmice were immunizedwith CpG-DOTAP (Figure 5), suggest-
ing that Th1 differentiation was largely intact in this circumstance
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Cell-Type-Specific Role of TLR in Immune ResponseFigure 2. The Physical Form of CpG Influences Its Interaction with Immune Cells
(A) Wild-type mice were injected i.v. with CpG, Cy5.5-labeled CpG, or Cy5.5-labeled CpG complexed with DOTAP. After 30 min, uptake of CpG was examined
by flow cytometry on gated conventional DCs (cDCs; CD11chiI-Ab+), plasmacytoid DCs (pDCs; CD11cintB220+Ly6C+CD19), macrophages (Mf; CD11bintF4/
80hiLy6GSSChi), monocytes (Mo; CD11b+F4/80+Ly6C+CD11cLy6GSSClo) or NK cells (NK1.1+TCRb) in the spleen. Shown are representative FACS plots
for one of two mice per group.
(B) Splenic CD11chi DCs of wild-type mice were stained for intracellular IL-12p40 1 hr after injection with the indicated TLR ligands. Shown are representative
FACS plots for one of four mice per group analyzed on two separate days.
(C) Control or DC-Myd88/ mice were injected i.v. with indicated TLR ligands. After 1 hr, splenocytes were stained for intracellular TNF-a. Shown are
representative contour plots of gated CD11b+F4/80+Ly6C+SSCloCD11cNK1.1B220 cells from one of four mice per group analyzed on two separate
days.
276 Immunity 29, 272–282, August 15, 2008 ª2008 Elsevier Inc.
Immunity
Cell-Type-Specific Role of TLR in Immune ResponseFigure 3. Role of MyD88 in DCs for the IFN-g Response of NK Cells to TLR Stimulation In Vivo
(A and B) Mice were injected with the indicated TLR ligands. Five hours later, synthesis of IFN-g by splenic NK cells (NK1.1+TCRb) was assessed by intracellular
staining and flow cytometry. (A) Representative contour plots of control or DC-Myd88/mice from one of six mice per group analyzed on two separate days. (B)
Representative contour plot of wild-type (C57BL/6), Il12a/, Ifnar1/, and Myd88/ mice from one of four mice per group analyzed on two separate days.whereMyD88 signaling in cells other than DCs plays amore prom-
inent role in cytokine production and in induction of DCmaturation.
Interestingly, mice immunized with OVA and LPS also exhibited
strong expansion of OT-II CD4+ T cells and differentiation to Th1
cells in both control and DC-Myd88/ mice (data not shown).
B Cell Antibody Production and Isotype Switching
in the DC-Myd88/ Mice
Th1 cells secrete cytokines, including IFN-g, to induce class
switch to IgG2c and IgG2b by responding B cells. As an alter-native readout for Th1 development, we examined antibody
responses after immunizing mice with OVA plus either CpG or
CpG-DOTAP. Although roughly similar amounts of anti-OVA
IgM were induced in control and DC-Myd88/ mice, total IgG
titers were significantly reduced in DC-Myd88/ mice immu-
nized with OVA and CpG (Figure 6, upper panel). In addition,
there was even more drastically reduced production of IgG2c
and IgG2b OVA-specific antibody in the DC-Myd88/ mice. In
contrast, immunization with OVA and CpG-DOTAP induced
comparable amounts of total IgG and IgG1, aswell as substantial(D) Induction of inflammatory-cytokine mRNA in the spleen at 1 hr after injection i.v. with CpG complexed with DOTAP. n-fold induction and n-fold difference
were calculated as in Figure 1. Statistical comparison is between the DC-Myd88/mice and the control mice. *, p < 0.05; **, p < 0.01. Data are representative of
two separate experiments.
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Cell-Type-Specific Role of TLR in Immune ResponseFigure 4. Defects in DC Maturation in the DC-Myd88/ Mice
(A) Control or DC-Myd88/mice were injected i.v. with CpG or CpG-DOTAP. After 12 hr, expression of CD86 (left), CD40 (middle), or I-Ab (right) on the surface of
CD11chi DCswere assessed by flow cytometry. n-fold induction (mean + SD of fourmice) ofmedian fluorescence intensity (MFI) is relative to the expression levels
in vehicle-treated mice. Statistical comparison is between the DC-Myd88/ mice and the control mice. *, p < 0.05; **, p < 0.01.
(B) Representative histograms of CD86 (left), CD40 (middle), or I-Ab (right) on gated CD11chi DCs from control,Myd88/, or DC-Myd88/ mice 12 hr after i.v.
injection of CpG or CpG-DOTAP. Gray histograms represent wild-type mice injected with PBS (upper) or DOTAP (lower).amounts of IgG2c and IgG2b OVA-specific antibodies in the DC-
Myd88/ mice, although the titers were slightly reduced com-
pared to control mice (Figure 6, lower panel). Similar results to
those seen with OVA and CpG-DOTAP were seen when mice
were immunized with OVA and LPS (data not shown). Thus, as
in the case of effector Th1 differentiation, the T cell-dependent
IgG response to OVA and CpG was largely dependent on
MyD88 function in DCs. However, changing the physical form
of the TLR ligand, in this case CpG, to a more aggregated form
enhanced cytokine production from other cell types, which prob-
ably contributed to the observed T cell-dependent antibody
response.
DISCUSSION
In the experiments described here, we have examined the role of
TLRs on different immune cell types for the rapid production of
inflammatory cytokines and for the activation of the adaptive im-
278 Immunity 29, 272–282, August 15, 2008 ª2008 Elsevier Inc.mune response. Experiments employing a new conditional allele
of the gene encoding the key TLR signaling-adaptor molecule,
MyD88, together with DC-specific expression of the Cre recom-
binase, revealed a critical role for TLR signaling in DCs for many
responses to TLR ligands. These experiments also revealed sit-
uations where other cell types can contribute importantly to the
production of certain inflammatory cytokines and relieve the re-
quirement for DC-intrinsic TLR signaling in order to stimulate
a vigorous Th1 response.
These experiments provide evidence for the view that the di-
rect recognition of microbial ligands by TLRs on DCs plays
a prominent role for the initiation of the adaptive immune re-
sponse and for directing polarization to a Th1 response. When
mice were immunized with ovalbumin and soluble CpG, Th1
polarization of ovalbumin-specific CD4+ T cells was greatly
diminished by deletion of the Myd88 gene selectively in DCs.
This result is consistent with a previous study using wild-
type and MyD88-deficient bone-marrow chimeras (Spo¨rri and
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that DCs lackingMyD88 had substantially compromisedmatura-
tion in response to soluble CpG administered i.v., as indicated by
the reduced induction of costimulatorymolecules. Amajor differ-
ence between those experiments and the ones described here is
that in the bone-marrow chimeric mice, there was a mixture of
MyD88-expressing DCs and MyD88-deficient DCs, whereas in
the experiments described here, the vast majority of the DCs
Figure 5. Clonal Expansion and Development of Th1 Effector T Cells
in the DC-Myd88/ Mice
(A) Purified CD4+ T cells from OT-II-transgenic mice with a congenic marker
(Thy1.1+) were labeled with CFSE and adoptively transferred into Thy1.2+
DC-Myd88/ and control mice. One day later (day 0), the mice were immu-
nized (i.v.) with OVA mixed with CpG (upper panels) or OVA mixed with
CpG-DOTAP (lower panels). On days 4 or 7, lymphocytes from the spleen
were harvested and restimulated in vitro with PMA and ionomycin for 4 hr.
The proliferation of OT-II T cells (identified as CD4+B220Thy1.1+) was tracked
by CFSE dilution, and development of Th1 effector function was assessed by
intracellular IFN-g staining and flow cytometry. Shown are representative dot
plots of intracellular IFN-g staining and CFSE dilution on day 4 of single mice
immunized with OVA and CpG or OVA and CpG-DOTAP. Numbers in the gates
indicate percentage of OT-II T cells that were IFN-g+.
(B) Absolute numbers of OT-II T cells (left panel) and IFN-g+ OT-II T cells (right
panel) in the spleen at day 4 after immunization with OVA and CpG or OVA and
CpG-DOTAP and in vitro restimulation, as calculated from the counts of total
splenocytes and the percentages of OT-II T cells and IFN-g+ OT-II T cells in
the spleens. Data are expressed as mean + SD of four mice and are represen-
tative of three separate experiments. Statistical comparison is between the
DC-Myd88/ mice and the control mice. *, p < 0.05.were MyD88 deficient and other cell types retained MyD88 ex-
pression. Therefore, the indirect maturation observed in the
bone-marrow chimeric mice probably reflects the action of cyto-
kines produced primarily by neighboring DCs, acting in a para-
crine manner. This interpretation is supported by observations
reported here that DCs were the major cell types producing cy-
tokines in response to soluble TLR ligands. Taken together, our
results and those of Spo¨rri and Reis e Sousa (2005) demonstrate
the importance of TLR signaling in DCs for CD4+ T cell re-
sponses, at least in the context of immunization with soluble
TLR ligands.
MyD88 function in DCs was found to be especially important
for IL-12 production in response to TLR ligand stimulation. IL-
12 is known to stimulate innate immune cell types such as NK
cells to express IFN-g and to promote the Th1 polarization of
CD4+ T cells (Magram et al., 1996), both of which can be en-
hanced by IL-18 (Takeda et al., 1998). Indeed, we found that
the early IFN-g production from NK cells and NKT cells in re-
sponse to soluble CpG was totally dependent on IL-12. IFN-g
from NK cells can initiate Th1 polarization of antigen-stimulated
CD4+ T cells (Martin-Fontecha et al., 2004) by inducing the fate-
determining transcription factor T-bet (Afkarian et al., 2002).
Figure 6. Antibody Response in the DC-Myd88/ Mice
Control and DC-Myd88/ mice were immunized i.p. with OVA together with
CpG (A) or CpG-DOTAP (B) and were bled 7 and 14 days after immunization.
Sera were serially diluted, and OVA-specific antibody isotypes (IgM on day 7
and total IgG, IgG1, IgG2b, and IgG2c on day 14) were measured by ELISA.
Data shown are the end-point titers of all samples. Statistical significance
was calculated with Mann-Whitney U test. *, p < 0.05 **, p < 0.01. Similar re-
sults were obtained in three (CpG) and two (CpG-DOTAP) separate experi-
ments.
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polarizing to Th1 cells by promoting their secretion of IFN-g.
Given the critical roles of IL-12 and the fact that its induction
by TLR ligands was highly dependent on direct TLR stimulation
in DCs, it is very likely that IL-12 was an essential cytokine for
promoting Th1 polarization under these circumstances. Thus,
TLR-MyD88 signaling in DCs probably contributes to adaptive
Th1 immune responses to immunization with soluble antigen
and TLR ligands in two main ways: by contributing to DC matu-
ration and by inducing IL-12 production.
We found that the physical form of the TLR ligand had a large
effect on the ability of different cell types to contribute to the im-
mune response in vivo. CpG presented in an aggregated form by
being complexed with the cationic lipid DOTAP induced a potent
type I IFN response compared to CpG alone, as reported previ-
ously (Honda et al., 2005). In contrast to the strong dependence
of MyD88 function in DCs on the cytokine responses to soluble
CpG, MyD88 function in both conventional DCs and other cell
types made important contributions to this response. Indeed,
whereas when soluble CpG was injected i.v., it was primarily
CD8a+ DCs in the spleen that made cytokines initially, when
CpG-DOTAP was injected i.v., both CD8a+ and CD8a DC sub-
sets responded rapidly, as did a F4/80+ cell type that may be the
inflammatory monocyte. In addition, pDCs were responsible for
most of the type I IFN production in response to CpG-DOTAP.
Interestingly, the uptake of CpG in these experiments was sub-
stantially enhanced when CpG was complexed with DOTAP.
The altered spectrum of responding cell types may relate to
changes in the mechanism of cell uptake, and it has been re-
ported that CpG-DOTAP complexes enter cells through the en-
docytic pathway (Zabner et al., 1995). Interestingly, interaction
of self-DNA with a cationic amphipathic antimicrobial peptide
LL37 has recently been implicated in the pathogenesis of psori-
asis. This complex, whichmay be similar in its action to the CpG-
DOTAP aggregate studied here, was found to greatly enhance
activation of pDCs in the affected skin of patients with psoriasis
(Lande et al., 2007). It is likely that many microbial and endoge-
nous TLR ligands exist in aggregated or particulate forms, so the
ability of both DCs and other myeloid cell types to respond to
TLR ligands presented in these complex forms may be relevant
to many biological situations.
Theability ofCpG-DOTAP to induce largeamountsof type I IFNs
frompDCs, as well as from other non-DC cell types, is likely to ex-
plain its ability to induce strong IFN-gproduction fromNKcells, ro-
bust DC maturation, and a vigorous Th1 response in the absence
of MyD88 expression in DCs. Other have reported that type I IFNs
can synergize with IL-18 to induce IFN-g even in IL-12-deficient
splenocyte cultures (Freudenberg et al., 2002), and we found
that the NK cell IFN-g response to CpG-DOTAP was largely de-
pendent on the expression of type I IFN receptors. In addition,
type I IFNs are known to be able to induce maturation of DCs
(Hoebe and Beutler, 2004). Indeed, it has been shown that coad-
ministration of IFN-awith antigen induces delayed-type hypersen-
sitivity (Gallucci et al., 1999), as well as IgG2a antibody production
(LeBonetal., 2001),bothofwhichare typical Th1 responses.Thus,
the robust production of type I IFNs by cell types other than con-
ventional DCs is likely to explain why MyD88 function in DCs was
not necessary for DC maturation or for a vigorous Th1 response
in DC-Myd88/mice immunized with OVA and CpG-DOTAP.
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that of CpG-DOTAP. LPS is an amphipathic component of gram-
negative bacterial cell walls that forms large aggregates in solu-
tion, so it is not surprising that it has the ability to induce robust
cytokine responses from DC subsets and also from additional
myeloid cell types similarly to CpG-DOTAP. However, it is worth
noting that LPS, like CpG-DOTAP, neither induced IFN-g from
NK cells and NKT cells (Figure S5) nor promoted Th1 polarization
in Myd88/ mice (Schnare et al., 2001). Although TLR9 and
TLR4 both signal via MyD88, TLR4 also signals via the TRIF
adaptor, and this pathway induces abundant type I IFNs. Indeed,
previous work showed that LPS stimulation of Myd88/ mice
failed to promote Th1 responses despite a vigorous type I IFN re-
sponse and clearly evident DC maturation (Pasare and Medzhi-
tov, 2004). Thus, type I IFN production alone is insufficient to
drive Th1 responses. These results suggest that one or more
MyD88-dependent cytokines in addition to type I IFNs coming
from cells other than DCs are also required for the innate IFN-g
and Th1 response seen in DC-Myd88/ mice immunized with
CpG-DOTAP or LPS. IL-18 is known to synergize with type I
IFNs or IL-12 to induce IFN-g (Freudenberg et al., 2002;
Nakanishi et al., 2001) and therefore is a strong candidate for
the additional MyD88-dependent cytokine required for these
responses.
In any case, our results clearly show that the functional fate of
a T cell is not only affected by the DC that the T cell is interacting
with, but also by surrounding cells responding via TLRs and
MyD88. These surrounding cells include other DCs and non-DC
cell types in the infected tissues. This trans effect may allow
cooperation between cell types expressing different sets of
TLRs. For example, CD8a+ DCs, which do not express TLR7
(Edwards et al., 2003), can receive important cytokine signals
from pDCs, which secrete type I IFNs after TLR7 stimulation, al-
lowing them to activate T cells. Other recent studies have also
provided evidence for regulatory effects of macrophages on
DCs for polarizingTcell differentiation. For example, laminaprop-
ria macrophages from the gut were found to express anti-inflam-
matory cytokines even after TLR stimulation in vitro and to pro-
mote development of FoxP3+ regulatory T cells, which restrain
immune responses to commensal microbes and dietary anti-
gens, whereas DCs from the same location responded to the
same stimulus by producing proinflammatory cytokines and pro-
moting IL-17-producing T cell responses (Denning et al., 2007).
Clearly, much remains to be learned about how different types
of innate immune cells communicate with one another and com-
bine to direct the nature of the adaptive immune responses.
In summary, our results indicate that MyD88-dependent
signaling in both DCs and non-DC cell types can support Th1 dif-
ferentiation depending on the type of TLR stimulation. Whereas
direct TLR stimulation is likely to be themost efficient way for ac-
tivating DCs and for activating adaptive responses, we have
found that other cell types stimulated with TLR ligands in com-
plex forms secrete substantial amounts of cytokines that can
make important contributions to both innate and adaptive im-
mune responses. It should be very interesting to use themice de-
scribed here to dissect further the role of TLR signaling in differ-
ent cell types for activation of adaptive immune responses in
more complicated and biologically important situations, such
as infections with pathogens and autoimmune diseases.
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Generation of the Myd88fl Allele
A conditional allele ofMyd88 was created in mouse E14 embryonic stem cells
(ESCs) following standard procedures (see Supplemental Experimental Proce-
dures for details). Out of 400 ESC clones screened, five had recombined into
the endogenous Myd88 locus. Three independent lines of the homologously
recombined ESCs were injected into blastocysts from B6 mice by the UCSF
mouse genetic core facility, and animals with high levels of incorporation of
the 129 ESCs into the embryo were obtained. The mice were bred, and germ-
line transmission of the targeted allele was obtained in mice originating from
the three ESC lines. The offspring were then bred to ACTB-FLPe mice, which
express FLP recombinase (Rodriguez et al., 2000), to remove the neomycin re-
sistance cassette. This leaves the conditional allele with two loxP sites and one
residual FRT site.
Mice
B6 (000664; C57BL/6J) and B6-Thy1.1 (001317; B6.Cg-Igha Thy1a Gpi1a/J)
mice were from Jackson Laboratory. ACTB-FLPe mice (Rodriguez et al.,
2000) were obtained from G. Martin (UCSF). CD11c-Cre mice have been de-
scribed (Caton et al., 2007), and the mice used in this study were backcrossed
to B6 for at least six generations. Vav-Cremice (de Boer et al., 2003) were a gift
of D. Kioussis (National Institute forMedical Research, London, UK).Myd88/
mice (Adachi et al., 1998) were originally from S. Akira (Osaka University,
Osaka, Japan) and were backcrossed to B6 for ten generations in our colony.
Mice deficient in IL-12p35 (Il12a/) (Mattner et al., 1996) were obtained from
R. Locksley (UCSF). Ifnar1/mice (Muller et al., 1994) were obtained from M.
Matloubian (UCSF). OT-II mice (Barnden et al., 1998) were bred to B6-Thy1.1
mice, and the F1 male mice were used as the donors of TCR-transgenic CD4
T cells.
TheMyd88fl mice used in this study were backcrossed to B6 for at least six
generations and then crossed toCD11c-Cremice or Vav-Cre-transgenicmice.
In this study,Myd88fl/fl orMyd88fl/mice containing the CD11c-Cre transgene
or the Vav-Cre transgene were used, and Myd88fl/fl or Myd88fl/ mice were
used as controls.
All experimental mice were used at 8–12 weeks of age and were sex
matched and age matched (within 2 weeks) within experiments. All animals
were housed in a specific pathogen-free animal facility at UCSF under condi-
tions that meet institutional animal care and use committee (IACUC) and
National Institutes of Health (NIH) guidelines.
Reagents
CpG oligodeoxynucleotide 1826 containing a phosphorothioate backbone
(CpG) and Cy5.5-labeled CpG were purchased from Integrated DNA Technol-
ogies (IDT). For making the CpG-DOTAP complex, 25 mg of CpGwas diluted in
75 ml of 20 mM HEPES-buffered saline (HBS) and then mixed with 50 mg of
DOTAP (Roche) diluted to 75 ml with HBS for 15 min before injection. Ultrapure
LPS (E.coli 0111:B4), Pam3CSK4, and imiquimod (R837) were purchased from
Invivogen. Salmonella typhimurium flagellin was purified from a fljBfliC+ strain
(TH4778, kindly provided by K. Hughes, University of Utah, UT), following
a protocol provided by K.D. Smith (University ofWashington, WA). Chicken ov-
albumin was purchased from Sigma-Aldrich, and endotoxin was removed by
Triton X-114 treatment as described (Aida and Pabst, 1990). All reagents
were free of endotoxin as determined by the Limulus Amebocyte Lysate
Test (BioWhittaker).
Quantitative PCR
For assessing the deletion efficiency in particular cell types of theDC-Myd88/
mice, genomic DNA was extracted from FACS-purified cells, and the residual
amount of the ‘‘floxed’’ region was quantified by Taqman PCR (see Supple-
mental Experimental Procedures for details). The amount of flox allele of
each mouse was normalized to Edg-1. The genomic DNA from Myd88fl/fl
mice was used for the no-deletion control.
For quantifying cytokine induction after systemic administration of TLR li-
gands, mouse spleens were harvested and snap frozen in liquid nitrogen. Total
RNA was extracted with the RNeasy kit (QIAGEN) with on-column DNase di-
gestion. cDNAwas transcribed from total RNAwith the iScript cDNA Synthesis
Kit (Bio-Rad). Transcripts were quantified by PCR with iTaq SYBR GreenSupermix with ROX (Bio-Rad), and the levels of cytokine transcripts were nor-
malized to the levels of HPRT mRNA. The induction of cytokine mRNA was
expressed as a ratio between the mRNA value of the TLR-ligand-treated
mice and that of the vehicle-treated control mice. All primers (Table S3) were
obtained from IDT.
Enzyme-Linked Immunosorbent Assay
The amounts of cytokines in serum were analyzed by standard sandwich en-
zyme-linked immunosorbent assay (ELISA) kits (BD Biosciences). The titers of
OVA-specific immunoglobulin isotypes in serum were determined by ELISA
with horseradish peroxidase (HRP)-conjugated anti-mouse IgM, total IgG,
IgG1, IgG2b, or IgG2c reagents (Southern Biotech) to detect immunoglobulin
bound to theOVA-coated plates. Antibody titers were determined as the recip-
rocal of the dilution that gave an optical density value (450–570 nm wave-
length) that was more than ten times the standard deviation above the mean
value of the negative-control wells.
Flow Cytometry
For surface staining of DCs, single-cell suspensions were prepared from
spleens with the digestion medium (see Supplemental Experimental Proce-
dures). The cells were then stained in ice-cold FACS buffer (PBS supple-
mented with 2 mMEDTA, 1% heat-inactivated FCS, and 0.02% sodium azide).
Anti-CD16/CD32 (Ab) (2.4G2, BD PharMingen) was used to block nonspecific
antibody binding. All fluorochrome-conjugated monoclonal antibodies were
purchased from BD PharMingen or eBioscience.
To detect in vivo IL-12, TNF-a, or IFN-g expression in particular cell types,
splenocytes were prepared, and surface markers were stained as described
above with the exception that all media contained 10 mg/ml brefeldin A
(Sigma-Aldrich). Then the cells were fixed and permeabilized with the Cyto-
fix/Cytoperm kit (BD Biosciences). Intracellular IL-12 was detected by phyco-
erythrin- or allophycocyanin-labeled IL-12p40/p70-specific antibody (C15.6,
BD PharMingen), TNF-a was detected by phycoerythrin-labeled TNF-a-spe-
cific antibody (MP6-XT22, BD PharMingen), and IFN-g was detected by allo-
phycocyanin-labeled IFN-g-specific antibody (XMG1.2 BD PharMingen).
For assessment of ex vivo T cell IFN-g expression, single-cell suspensions
were prepared from the spleen, and 5 3 106 cells/ml were cultured for 4 hr
in complete RPMI-1640 medium (10% heat-inactivated FCS, 25 mM HEPES,
1 mM L-glutamine, 50 mM 2-mercaptoethanol) containing 100 pg/ml PMA and
1 ng/ml ionomycin. Brefeldin A (10 mg/ml) was added for the last 2 hr of culture.
Then the intracellular IFN-g was stained as described above.
All data were collected on a LSRII flow cytometer (Becton Dickinson) and
were analyzed with FlowJo software (TreeStar).
Adoptive Transfer
Purified OT-II T cells (5 3 105) were labeled with 5 mM carboxyfluorescein
diacetate succinimidyl ester (CFSE) (Molecular Probes) for 8 min at 37C
and then transferred into sex-matched recipient mice by intravenous injection
1 day before immunization.
In Vivo Stimulation of TLRs and Immunization
For in vivo stimulation, mice were injected with TLR ligands either intrave-
nously (CpG 25 mg, Cy5.5-labeled CpG 25 mg, LPS 25 mg, Pam3CSK4
50 mg, flagellin 20 mg, or CpG-DOTAP complex 25 mg/50 mg) or intraperitoneally
(imiquimod 150 mg).
Mice were immunized with 50 mg OVA mixed with 25 mg CpG or with CpG-
DOTAP (25 mg/50 mg) intraperitoneally for antibody response, or intravenously
for T cell responses. Sera and lymphoid organs were collected at the indicated
times.
Statistical Analysis
Statistical significance was calculated with an unpaired Student’s t test or
Mann-Whitney U test. All p values of 0.05 or less were considered significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
tables, and five figures and can be found with this article online at http://
www.immunity.com/cgi/content/full/29/2/272/DC1/.
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